Use of Preferentially Replicating Bacteria for the Treatment of Cancer

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2000 Apr 20

PMID 10772643

Citations 65

Authors

M Sznol

S L Lin

D Bermudes

L M Zheng

I King

Affiliations

Soon will be listed here.

Citing Articles

Precision tumor treatment utilizing bacteria: principles and future perspectives.

Liu Z, Wang L, Wu P, Yuan L Appl Microbiol Biotechnol. 2025; 109(1):2.

PMID: 39754636 PMC: 11700060. DOI: 10.1007/s00253-024-13378-x.

Remolding the tumor microenvironment by bacteria augments adoptive T cell therapy in advanced-stage solid tumors.

Zhu C, Liu C, Wu Q, Sheng T, Zhou R, Ren E Signal Transduct Target Ther. 2024; 9(1):307.

PMID: 39572541 PMC: 11582571. DOI: 10.1038/s41392-024-02028-3.

Advancements in tantalum based nanoparticles for integrated imaging and photothermal therapy in cancer management.

Ifijen I, Christopher A, Lekan O, Aworinde O, Faderin E, Obembe O RSC Adv. 2024; 14(46):33681-33740.

PMID: 39450067 PMC: 11498270. DOI: 10.1039/d4ra05732e.

Dynamic Gene Expression Mitigates Mutational Escape in Lysis-Driven Bacteria Cancer Therapy.

Liguori F, Pellicciotta N, Milanetti E, Xi Windemuth S, Ruocco G, di Leonardo R Biodes Res. 2024; 6:0049.

PMID: 39301524 PMC: 11411163. DOI: 10.34133/bdr.0049.

Bacteria-Based Nanoprobes for Cancer Therapy.

Lu Y, Mei N, Ying Y, Wang D, Li X, Zhao Y Int J Nanomedicine. 2024; 19:759-785.

PMID: 38283198 PMC: 10821665. DOI: 10.2147/IJN.S438164.

References

MOESE J, MOESE G . ONCOLYSIS BY CLOSTRIDIA. I. ACTIVITY OF CLOSTRIDIUM BUTYRICUM (M-55) AND OTHER NONPATHOGENIC CLOSTRIDIA AGAINST THE EHRLICH CARCINOMA. Cancer Res. 1964; 24:212-6. View

THIELE E, ARISON R, BOXER G . ONCOLYSIS BY CLOSTRIDIA. III. EFFECTS OF CLOSTRIDIA AND CHEMOTHERAPEUTIC AGENTS ON RODENT TUMORS. Cancer Res. 1964; 24:222-33. View

ENGELBART K, GERICKE D . ONCOLYSIS BY CLOSTRIDIA. V. TRANSPLANTED TUMORS OF THE HAMSTER. Cancer Res. 1964; 24:239-42. View

Fox M, Lemmon M, Mauchline M, Davis T, Giaccia A, Minton N . Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia. Gene Ther. 1996; 3(2):173-8. View

Lemmon M, van Zijl P, Fox M, Mauchline M, Giaccia A, Minton N . Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment. Gene Ther. 1997; 4(8):791-6. DOI: 10.1038/sj.gt.3300468. View

Pawelek J, Low K, Bermudes D . Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res. 1997; 57(20):4537-44. View

Somerville Jr J, Cassiano L, Darveau R . Escherichia coli msbB gene as a virulence factor and a therapeutic target. Infect Immun. 1999; 67(12):6583-90. PMC: 97070. DOI: 10.1128/IAI.67.12.6583-6590.1999. View

Chen J, Sun Y, Nabel G . Regulation of the proinflammatory effects of Fas ligand (CD95L). Science. 1998; 282(5394):1714-7. DOI: 10.1126/science.282.5394.1714. View

Thorsteinsson L, ODowd G, Harrington P, Johnson P . The complement regulatory proteins CD46 and CD59, but not CD55, are highly expressed by glandular epithelium of human breast and colorectal tumour tissues. APMIS. 1998; 106(9):869-78. DOI: 10.1111/j.1699-0463.1998.tb00233.x. View

10.

Low K, Ittensohn M, Le T, Platt J, Sodi S, Amoss M . Lipid A mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo. Nat Biotechnol. 1999; 17(1):37-41. DOI: 10.1038/5205. View

11.

Schmitt C, Schwaeble W, Wittig B, Meyer zum Buschenfelde K, Dippold W . Expression and regulation by interferon-gamma of the membrane-bound complement regulators CD46 (MCP), CD55 (DAF) and CD59 in gastrointestinal tumours. Eur J Cancer. 1999; 35(1):117-24. DOI: 10.1016/s0959-8049(98)00290-1. View

12.

Galan J, Collmer A . Type III secretion machines: bacterial devices for protein delivery into host cells. Science. 1999; 284(5418):1322-8. DOI: 10.1126/science.284.5418.1322. View

13.

Jain R . Haemodynamic and transport barriers to the treatment of solid tumours. Int J Radiat Biol. 1991; 60(1-2):85-100. DOI: 10.1080/09553009114551621. View

14.

Guilloteau L, Lax A, Macintyre S, Wallis T . The Salmonella dublin virulence plasmid does not modulate early T-cell responses in mice. Infect Immun. 1996; 64(1):222-9. PMC: 173749. DOI: 10.1128/iai.64.1.222-229.1996. View